Related content

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

By Eap Chin   Buclin Thierry   Hustert Elisabeth   Bleiber Gabriela   Golay Kerry   Aubert Anne-Catherine   Baumann Pierre   Telenti Amalio   Kerb Reinhold  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 4, 2004-06 ,pp. : 231-236

Springer Publishing Company

Access to resources Recommend Favorite

Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism

By Araki K.   Yasui-Furukori N.   Fukasawa T.   Aoshima T.   Suzuki A.   Inoue Y.   Tateishi T.   Otani K.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 6, 2004-09 ,pp. : 427-430

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics of Selegiline in a Rabbit Model

By  

Letters in Drug Design & Discovery, Vol. 13, Iss. 8, 2016-10 ,pp. : 752-756

Bentham Science Publishers

Access to resources Recommend Favorite

Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam

By Drabant Sándor   Tóth Mária   Bereczki Andrea   Bajnógel Judit   Tömlö Judit   Klebovich Imre  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 587-588

Springer Publishing Company

Access to resources Recommend Favorite

Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects

By  

Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. : 151-157

John Wiley & Sons Inc

Access to resources Recommend Favorite